Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Estimates By $0.16 EPS

Royalty Pharma (NASDAQ:RPRX) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16, Zacks reports. Royalty Pharma had a net margin of 50.53% and a return on equity of 24.65%.

Royalty Pharma Stock Down 0.0 %

Shares of NASDAQ RPRX opened at $31.72 on Tuesday. The stock has a market capitalization of $18.69 billion, a P/E ratio of 16.44 and a beta of 0.49. Royalty Pharma has a one year low of $24.05 and a one year high of $32.21. The firm’s 50 day simple moving average is $27.93 and its two-hundred day simple moving average is $27.65. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be paid a $0.22 dividend. The ex-dividend date is Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.77%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio is currently 43.52%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. Finally, Citigroup reduced their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.